- Home
- CCD vs NMRA Comparison
CCD vs NMRA Comparison
Compare CCD & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CCD | NMRA |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 662.0M | 554.0M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | CCD | NMRA |
|---|---|---|
| Price | $24.45 | $1.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 85.7K | ★ 969.4K |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 10.61% | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.17 | $0.72 |
| 52 Week High | $26.10 | $3.65 |
Technical Indicators
Market Signals| Indicator | CCD | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.28 | 36.22 |
| Support Level | $23.81 | $1.46 |
| Resistance Level | $25.40 | $1.99 |
| Average True Range (ATR) | 0.58 | 0.11 |
| MACD | -0.11 | -0.00 |
| Stochastic Oscillator | 38.02 | 11.84 |
Price Performance
Historical ComparisonAbout CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.